Search - tctmd.com

Displaying 81 - 93 of 93

Sort: Relevancy | Date

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

Shelley Wood

March 18, 2017

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: First Results from the SURTAVI Clinical Trial

Presentation ACC 2017

First Results from the SURTAVI Clinical Trial

Presenter: Michael J. Reardon

March 17, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

Presentation ACC 2016

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis

Presenter: Vinod Thourani

April 01, 2016

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

Study Looks at Long-term Mortality Predictors in TAVR Patients

Jason Kahn

March 27, 2012

Presentation ACC 2012

Late (≥ 2 year) Clinical and Echocardiographic Outcomes after Transcatheter vs. Surgical Aortic Valve Replacement: Results from the High-Risk Cohort of The PARTNER Trial

Presenter: Susheel K. Kodali

March 26, 2012

Presentation ACC 2012

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

Presenter: Josep Rod?s-Cabau

March 24, 2012

News Conference News ACC 2012

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

March 24, 2012

News Conference News

TEST - COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

Shelley Wood

April 10, 2001

Advertisement

Live From Washington: ACC 2017, Day Three

Live From Washington: ACC 2017, Day Two

First Results from the SURTAVI Clinical Trial

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Study Looks at Long-term Mortality Predictors in TAVR Patients

Late (≥ 2 year) Clinical and Echocardiographic Outcomes after Transcatheter vs. Surgical Aortic Valve Replacement: Results from the High-Risk Cohort of The PARTNER Trial

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

TEST - COAPT Quality-of-Life Analysis Points to Significant, Sustained Benefits in Health Status With MitraClip

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content